Oncomed Pharmaceuticals India Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.40 M
- Company Age 8 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 926.16%
- Profit Growth 841.33%
- Ebitda -1255.30%
- Net Worth 93.45%
- Total Assets 946.22%
About Oncomed Pharmaceuticals India
Oncomed Pharmaceuticals India Private Limited (OPIPL) is a Private Limited Indian Non-Government Company incorporated in India on 18 August 2016 (Eight years and five months 27 days old ). Its registered office is in Patna, Bihar, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.40 M, as per Ministry of Corporate Affairs (MCA) records.
Deepak Kumar and Smita Khosla serve as directors at the Company.
Company Details
-
Location
Patna, Bihar, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24290BR2016PTC032302
-
Company No.
032302
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
18 Aug 2016
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Patna
Industry
What products or services does Oncomed Pharmaceuticals India Private Limited offer?
Oncomed Pharmaceuticals India Private Limited offers a wide range of products and services, including Autoclaves, Sterilizers & Incubators, Medical Refrigerator Systems, Warehouses and Warehousing Agents, Freezers.
Who are the key members and board of directors at Oncomed Pharmaceuticals India?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Deepak Kumar
|
Director | 18-Aug-2016 | Current |
|
Smita Khosla
|
Director | 18-Aug-2016 | Current |
Financial Performance of Oncomed Pharmaceuticals India.
Oncomed Pharmaceuticals India Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 926.16% increase. The company also saw a substantial improvement in profitability, with a 841.33% increase in profit. The company's net worth Soared by an impressive increase of 93.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Oncomed Pharmaceuticals India?
In 2020, Oncomed Pharmaceuticals India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Radiva Health Care Private LimitedDeepak Kumar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Oncomed Pharmaceuticals India?
Unlock and access historical data on people associated with Oncomed Pharmaceuticals India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Oncomed Pharmaceuticals India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Oncomed Pharmaceuticals India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.